



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/073,065
Filing Date	February 12, 2002
First Named Inventor	Shyam S. Mohapatra
Art Unit	1645
Examiner Name	(not yet assigned)

Sheet

1

of

3

Attorney Docket Number

USF-T156X

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner Signature

[Signature]

Date Considered

161910-3

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/073,065
Filing Date	February 12, 2002
First Named Inventor	Shyam S. Mohapatra
Group Art Unit	1645
Examiner Name	(not yet assigned)
Attorney Docket Number	USF-T156X

NOV 20 2002

RECEIVED
TECH CENTER 1600/290**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
32	R1	CHANOCK et al., "Serious Respiratory Tract Disease Caused by Respiratory Syncytial Virus: Prospects for Improved Therapy and Effective Immunization", Pediatrics, 1992, pp. 137-141	
	R2	CONNORS et al., "Respiratory Syncytial Virus (RSV) E, G, M2 (22K), and N Proteins Each Induce Resistance to RSV Challenge, but Resistance Induced by M2 and N Proteins Is Relatively Short-Lived", Journal of Virology, 1991, pp. 1634-1637, Vol. 65, No. 3	
	R3	WYATT et al., "Priming and Boosting Immunity to Respiratory Syncytial Virus by Recombinant Replication-Defective Vaccinia Virus MVA", Vaccine, 2000, pp. 392-397	
	R4	DOMACHOWSKE and ROSENBERG, "Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis, and Treatment", Clinical Microbiology Reviews, 1999, pp. 298-309, Vol. 12, No. 2	
	R5	BRANDENBURG et al., "Pathogenesis of RSV Lower Respiratory Tract Infection: Implications for Vaccine Development", Vaccine, 2001, pp. 2769-2782	
	R6	GROOTHUIS et al., "Use of Intravenous Gamma Globulin To Passively Immunize High-Risk Children Against Respiratory Syncytial Virus: Safety and Pharmacokinetics", Antimicrobial Agents and Chemotherapy, 1991, pp. 1469-1473, Vol. 35, No. 7	
	R7	HEMMING et al., "Hyperimmune Globulins in Prevention and Treatment of Respiratory Syncytial Virus Infections", Clinical Microbiology Reviews, 1995, pp. 22-33, Vol 8, No. 1	
	R8	LI et al., "Protection Against Respiratory Syncytial Virus Infection by DNA Immunization", J. Exp. Med., 1998, pp. 681-688, Vol. 188, No. 4	
	R9	LI et al., "Plasmid DNA Encoding the Respiratory Syncytial Virus G Protein Is a Promising Vaccine Candidate", Virology, 2000, pp. 54-65	
	R10	PRINCE et al., "Efficacy and Safety Studies of a Recombinant Chimeric Respiratory Syncytial Virus FG Glycoprotein Vaccine in Cotton Rats", 2000, pp. 10287-10292, Vol. 74, No. 22	
	R11	GUY et al., "Design, Characterization and Preclinical Efficacy of a Cationic Lipid Adjuvant for Influenza Split Vaccine", 2001, pp. 1794-1805	
32	R12	ROY et al., "Oral Gene Delivery With Chitosan-DNA Nanoparticles Generates Immunologic Protection in a Murine Model of Peanut Allergy", Nature Medicine, 1999, pp. 387-390	
32	R13	BEHERA et al., "Blocking Intercellular Adhesion Molecule-1 on Human Epithelial Cells Decreases Respiratory Syncytial Virus Infection", 2001, pp. 188-195	

Examiner Signature	<i>32</i>	Date Considered	10/18/03
--------------------	-----------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20591. PTO/SB/08B (10-01)



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	10/073,065
Filing Date	February 12, 2002
First Named Inventor	Shyam S. Mohapatra
Group Art Unit	1645
Examiner Name	(not yet assigned)
Attorney Docket Number	USF-T156X

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
32	R1	MATSUSE <i>et al.</i> , "Recurrent Respiratory Syncytial Virus Infections in Allergen-Sensitized Mice Lead to Persistent Airway Inflammation and Hyperresponsiveness", 2000, pp. 6583-6592
32	R2	MATSUO <i>et al.</i> , "Induction of Innate Immunity by Nasal Influenza Vaccine Administered in Combination with an Adjuvant (Cholera Toxin)", Vaccine, 2000, pp. 2713-2722
	R3	
	R4	
	R5	
	R6	
	R7	
	R8	
	R9	
	R10	
	R11	
	R12	
	R13	

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900

Examiner Signature		Date Considered	10/19/103
--------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20 PTO/SB/08B (10-01)

INFORMATION DISCLOSURE CITATION

RECEIVED

Atty. Docket No.	215101.03501	Appln. No.	10/073,065
Applicants	MOHAPATRA et al.		MAY 21 2002
Filing Date	February 12, 2002	Group:	1645

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
O/LP						
MAY 20 2002	JCB					
REMARKS OFFICE 89						


FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

32	Connors et al., "Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived", <i>J Virol</i> 65:1634, 1991
32	Wyatt et al, "Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA", <i>Vaccine</i> 18:392, 1999
32	Domachowske et al., "Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment," <i>Clin Microbiol Rev</i> 12:298, 1999)
32	Brandenburg et al., "Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development," <i>Vaccine</i> 19:2769, 2001
32	Groothuis et al., "Use of Intravenous Gamma Globulin To Passively Immunize High-Risk Children against Respiratory Syncytial Virus: Safety and Pharmacokinetics," <i>Antimicrobial Agents and Chemotherapy</i> , July 1991, pp. 1469-73.
32	Hemming et al., "Hyperimmune Globulins in Prevention and Treatment of Respiratory Syncytial Virus Infections," <i>Clin Microbiol Rev</i> . 1995 Jan;8(1):22-33. Review
32	Li et al, "Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate," <i>Virology</i> . 2000 Mar 30; 269(1): 54-65
32	Li et al, "Protection against respiratory syncytial virus infection by DNA immunization," <i>J Exp Med</i> 1998 Aug 17;188(4):681-8;
32	Prince et al, "Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats," <i>J Virol</i> . 2000 Nov;74(22): 10287-92
32	Guy et al, "Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine," <i>Vaccine</i> 19:1794, 2001

Examiner	<i>Sease</i>	Date Considered	<i>10/19/2003</i>
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/073,065
Sheet	1	of	2	Filing Date	February 12, 2002
				First Named Inventor	Shyam Mohapatra
				Group Art Unit	1645
				Examiner Name	
				Attorney Docket Number	USF-T156X

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1					
	U2					
	U3					
	U4					
	U5					
	U6					
	U7					
	U8					
	U9					
	U10					
	U11					
	U12					
	U13					
	U14					
	U15					
	U16					
	U17					

RECEIVED

FEB 24 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Office ³	Number ⁴				
ZL	F1	WO	98/02457	A1	Connaught Lab.	01-22-1998	All
ZL	F2	WO	02/44334	A2	Aviron, Inc.	06-06-2002	All
	F3						
	F4						
	F5						
	F6						
	F7						
	F8						
	F9						
	F10						

Examiner Signature	<i>Shyam Mohapatra</i>	Date Considered	10/8/03
--------------------	------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

2 of 2

Complete if Known

Application Number	10/073,065
Filing Date	February 12, 2002
First Named Inventor	Shyam Mohapatra
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	USF-T156X

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
32	R1	ANDERSON, L. "Respiratory syncytial virus vaccines for otitis media" <i>Vaccine</i> , 2001, 19:S59-S65.	
32	R2	KUMAR, M. et al. "A RSV Genome Chitosan Nanosphere (RGCN) Vaccine Against Respiratory Syncytial Virus (RSV) Infection" <i>J. Allergy and Clin. Immuno.</i> , February 2001, 2(107):S251 (abstract).	
32	R3	WHITEHEAD, S. S. et al. "Recombinant Respiratory Syncytial Virus Bearing a Deletion of either the NS2 or SH Gene is Attenuated in Chimpanzees" <i>J. Virology</i> , April 1999, 73(4):3438-3442.	
	R4		
	R5		RECEIVED
	R6		FEB 24 2003
	R7		TECH CENTER 1600/2900
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature

Date Considered

10/18/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.